Intravitreal aflibercept for macular oedema secondary to central retinal vein occlusion in patients with prior treatment with bevacizumab or ranibizumab

被引:25
作者
Papakostas, T. D. [1 ]
Lim, L. [1 ]
van Zyl, T. [1 ]
Miller, J. B. [1 ]
Modjtahedi, B. S. [1 ]
Andreoli, C. M. [2 ]
Wu, D. [1 ]
Young, L. H. [1 ]
Kim, I. K. [1 ]
Vavvas, D. G. [1 ]
Esmaili, D. D. [3 ]
Husain, D. [1 ]
Eliott, D. [1 ]
Kim, L. A. [1 ]
机构
[1] Harvard Univ, Massachusetts Eye & Ear Infirm, Sch Med, Retina Serv, Boston, MA USA
[2] Harvard Vanguard Med Associates, Boston, MA USA
[3] Retina Vitreous Associates Med Grp, Los Angeles, CA USA
关键词
VEGF TRAP; PHASE-III; DEGENERATION; TRIAL; INJECTION; OUTCOMES; THERAPY; GALILEO; EYE;
D O I
10.1038/eye.2015.175
中图分类号
R77 [眼科学];
学科分类号
100212 ;
摘要
Purpose To report the visual and anatomic outcomes in eyes with macular oedema (MO) secondary to central retinal vein occlusion (CRVO) that were switched from either intravitreal bevacizumab or ranibizumab to intravitreal aflibercept. Methods Two-center retrospective chart review. Eyes with MO secondary to CRVO that received a minimum of three intravitreal injections of bevacizumab or ranibizumab and were switched to intravitreal aflibercept for persistent or recurrent MO not responding to either bevacizumab and/or ranibizumab. Results In all 42 eyes of 42 patients were included in the study. The median visual acuity before the switch was 20/126, 1 month after the first injection of aflibercept 20/89 (P=0.0191), and at the end of the follow-up 20/100 (P=0.2724). The median CRT before the switch was 536 mu m, 1 month after the first injection of aflibercept 293.5 mu m (P=0.0038), and at the end of the follow-up 279 mu m (P=0.0013 compared to before the switch). The median number of weeks between injections before the switch was 5.6 and after the switch was 7.6 (P < 0.0001). Conclusion Converting eyes with refractory MO due to CRVO to aflibercept can result in stabilization of the vision, improved macular anatomy, and extension of the injection interval.
引用
收藏
页码:79 / 84
页数:6
相关论文
共 21 条
[1]   Aflibercept Therapy for Exudative Age-related Macular Degeneration Resistant to Bevacizumab and Ranibizumab [J].
Bakall, Benjamin ;
Folk, James C. ;
Boldt, H. Culver ;
Sohn, Elliott H. ;
Stone, Edwin M. ;
Russell, Stephen R. ;
Mahajan, Vinit B. .
AMERICAN JOURNAL OF OPHTHALMOLOGY, 2013, 156 (01) :15-22
[2]   Predictive Value in Retinal Vein Occlusions of Early Versus Late or Incomplete Ranibizumab Response Defined by Optical Coherence Tomography [J].
Bhisitkul, Robert B. ;
Campochiaro, Peter A. ;
Shapiro, Howard ;
Rubio, Roman G. .
OPHTHALMOLOGY, 2013, 120 (05) :1057-1063
[3]   Vascular Endothelial Growth Factor Trap-Eye for Macular Edema Secondary to Central Retinal Vein Occlusion Six-Month Results of the Phase 3 COPERNICUS Study [J].
Boyer, David ;
Heier, Jeffrey ;
Brown, David M. ;
Clark, W. Lloyd ;
Vitti, Robert ;
Berliner, Alyson J. ;
Groetzbach, Georg ;
Zeitz, Oliver ;
Sandbrink, Rupert ;
Zhu, Xiaoping ;
Beckmann, Karola ;
Haller, Julia A. .
OPHTHALMOLOGY, 2012, 119 (05) :1024-1032
[4]  
Boyer D, 2010, OPHTHALMOLOGY, V117, P1860, DOI 10.1016/j.ophtha.2010.02.022
[5]   Intravitreal Aflibercept Injection for Macular Edema Secondary to Central Retinal Vein Occlusion: 1-Year Results From the Phase 3 COPERNICUS Study [J].
Brown, David M. ;
Heier, Jeffrey S. ;
Clark, W. Lloyd ;
Boyer, David S. ;
Vitti, Robert ;
Berliner, Alyson J. ;
Zeitz, Oliver ;
Sandbrink, Rupert ;
Zhu, Xiaoping ;
Haller, Julia A. .
AMERICAN JOURNAL OF OPHTHALMOLOGY, 2013, 155 (03) :429-437
[6]   Sustained Benefits from Ranibizumab for Macular Edema following Central Retinal Vein Occlusion: Twelve-Month Outcomes of a Phase III Study [J].
Campochiaro, Peter A. ;
Brown, David M. ;
Awh, Carl C. ;
Lee, S. Young ;
Gray, Sarah ;
Saroj, Namrata ;
Murahashi, Wendy Yee ;
Rubio, Roman G. .
OPHTHALMOLOGY, 2011, 118 (10) :2041-2049
[7]  
CLARKSON JG, 1995, OPHTHALMOLOGY, V102, P1425
[8]   RESPONSE TO AFLIBERCEPT AS SECONDARY THERAPY IN PATIENTS WITH PERSISTENT RETINAL EDEMA DUE TO CENTRAL RETINAL VEIN OCCLUSION INITIALLY TREATED WITH BEVACIZUMAB OR RANIBIZUMAB [J].
Eadie, James A. ;
Ip, Michael S. ;
Kulkarni, Amol D. .
RETINA-THE JOURNAL OF RETINAL AND VITREOUS DISEASES, 2014, 34 (12) :2439-2443
[9]   Dexamethasone Intravitreal Implant in Patients with Macular Edema Related to Branch or Central Retinal Vein Occlusion [J].
Haller, Julia A. ;
Bandello, Francesco ;
Belfort, Rubens, Jr. ;
Blumenkranz, Mark S. ;
Gillies, Mark ;
Heier, Jeffrey ;
Loewenstein, Anat ;
Yoon, Young Hee ;
Jiao, Jenny ;
Li, Xiao-Yan ;
Whitcup, Scott M. .
OPHTHALMOLOGY, 2011, 118 (12) :2453-2460
[10]   Intravitreal Aflibercept Injection for Macular Edema Due to Central Retinal Vein Occlusion [J].
Heier, Jeffrey S. ;
Clark, W. Lloyd ;
Boyer, David S. ;
Brown, David M. ;
Vitti, Robert ;
Berliner, Alyson J. ;
Kazmi, Husain ;
Ma, Yu ;
Stemper, Brigitte ;
Zeitz, Oliver ;
Sandbrink, Rupert ;
Haller, Julia A. .
OPHTHALMOLOGY, 2014, 121 (07) :1414-U143